Hong Kong College of Physicians Position Statement and Recommendations on the 2017 American College of Cardiology/American Heart Association and 2018 European Society of Cardiology/European Society of Hypertension Guidelines for the Management of Arterial Hypertension

KK Chan *, CC Szeto, Christopher CM Lum, PW Ng, Alice PS Kong, KP Lau, Jenny YY Leung, SL Lui, KL Mo, Francis CK Mok, Vincent CT Mok, Bryan PY Yan, Philip KT Li *

ABSTRACT
The American College of Cardiology/American Heart Association released guidelines for the prevention, detection, evaluation, and management of high blood pressure (BP) in adults in 2017. In 2018, the European Society of Cardiology (ESC)/European Society of Hypertension (ESH) published new guidelines for the management of arterial hypertension. Despite the many similarities between these two guidelines, there are also major differences in the guidelines in terms of diagnosis and treatment of hypertension. A working group of the Hong Kong College of Physicians (HKCP) convened and conducted a focused discussion on important issues of public interest, including classification of BP, BP measurement, thresholds for initiation of antihypertensive medications, BP treatment targets, and treatment strategies. The HKCP concurs with the 2018 ESC/ESH guideline on BP classification, which defines hypertension as office systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg. The HKCP also acknowledges the growing evidence of home BP monitoring and ambulatory BP monitoring in the diagnosis and monitoring of hypertension and endorses the wider use of both methods. The HKCP also supports the direction of a risk-based approach for initiation of antihypertensive medications and the specification of a treatment target range for both systolic and diastolic BP with consideration of different age-groups and specific disease subgroups. Non-pharmacological interventions are crucial, both at the societal and individual patient levels. The recent guideline publications provide good opportunities to increase public awareness of hypertension and encourage lifestyle modifications among the local population.

Introduction
In 2017, the American College of Cardiology (ACC)/American Heart Association (AHA) released a guideline for the prevention, detection, evaluation, and management of high blood pressure (BP) in adults. This guideline was a collaborative effort by 11 organisations that updated the JNC7 (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure) in 2003. In 2018, the European Society of Cardiology (ESC)/European Society of Hypertension (ESH) published a new guideline for the management of arterial hypertension. Both the European and American guidelines provide comprehensive...
information for the clinical and public-health practice communities on high BP management. There are many similarities between these two sets of guidelines: both emphasise the importance of accurate BP measurement and encourage out-of-office BP measurement for confirmation of hypertension diagnosis. Both sets of guidelines also recommend cardiovascular disease risk estimation for risk stratification and a core strategy of non-pharmacological lifestyle interventions and drug treatment, including combination drug therapy. Despite the many similarities between these two guidelines, the guidelines also have major differences in terms of diagnosis and treatment of hypertension.

Hypertension is prevalent in Hong Kong. In a population health survey in 2014/15 conducted by Department of Health,4 the prevalence of hypertension (systolic BP [SBP] ≥140 mm Hg and/or diastolic BP [DBP] ≥90 mm Hg) was 27.7% among persons aged 15 to 84 years, with 47.5% of them having been undiagnosed before the survey. The prevalence of hypertension increased steadily with age, from 4.5% among those aged 15 to 24 years to 64.8% among those aged 65 to 84 years.

A working group of the Hong Kong College of Physicians (HKCP) convened and conducted a focused discussion on important issues of public interest pertaining to these two guidelines. This document formulates the HKCP’s views on the following issues: (1) classification of BP; (2) BP measurement; (3) thresholds for initiation of antihypertensive medications; (4) BP treatment targets; and (5) treatment strategies.

Classification of blood pressure

The 2018 ESC/ESH guideline defines hypertension as office SBP ≥140 mm Hg and/or DBP ≥90 mm Hg (Table 1). This definition remains unchanged from the previous 2013 ESC/ESH guideline.5 However, the 2017 ACC/AHA guideline contains a new BP classification that proposes a lower threshold to define hypertension (SBP ≥130 mm Hg and/or DBP ≥80 mm Hg). The same guideline defines normal BP as <120/80 mm Hg and elevated BP as 120 to 129 mm Hg SBP and <80 mm Hg DBP.

The Systolic Blood Pressure Intervention Trial is an important trial that significantly influenced the recommendations of the 2017 ACC/AHA guidelines.6 The method used for office BP measurement in the Systolic Blood Pressure Intervention Trial was unattended automatic measurement, in which automated multiple BP readings in a doctor’s office are obtained with the patient seated alone and unobserved. This method has not been used in any previous randomised controlled trials that provide an evidentiary basis for the treatment of hypertension. The relationship between conventional office BP measurement and unattended office BP measurement remains unclear, but available evidence suggests that conventional office SBP readings may be at least 5 to 15 mm Hg higher.7

The 2017 ACC/AHA guideline’s definition of hypertension is controversial. According to that new definition, about 46% of adults in the US have hypertension, as compared with about 32% under the previous definition.1 This corresponds to an increase in the number of eligible patients requiring treatment by more than 7 million in the US and more than 55 million in China.7 The potential implications for management of patients with hypertension are...
TABLE 2. Definitions of hypertension according to office, ambulatory, and home blood pressure levels

<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic BP (mm Hg)</th>
<th>Diastolic BP (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office BP*</td>
<td>≥140 and/or</td>
<td>≥90</td>
</tr>
<tr>
<td>Ambulatory BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daytime (or awake) mean</td>
<td>≥135 and/or</td>
<td>≥85</td>
</tr>
<tr>
<td>Night-time (or asleep) mean</td>
<td>≥120 and/or</td>
<td>≥70</td>
</tr>
<tr>
<td>24-Hour mean</td>
<td>≥130 and/or</td>
<td>≥80</td>
</tr>
<tr>
<td>Home BP mean</td>
<td>≥135 and/or</td>
<td>≥85</td>
</tr>
</tbody>
</table>

Abbreviation: BP = blood pressure
* Conventional office BP rather than unattended office BP

Blood pressure measurement

Both the European and American guidelines strongly emphasise accurate BP measurement and recording and consideration of readings in various settings as needed. A description detailing the steps of accurate BP measurement is provided (ie, having the patient sit quietly for 5 minutes before measurement, supporting the limb used to measure BP, ensuring that the BP cuff is at heart level, and using the correct cuff size). Out-of-office BP measurements are recommended in patients with suspected white coat hypertension, for confirmation of the diagnosis of hypertension, and for titration of BP-lowering medication, in conjunction with telehealth counselling or clinical interventions.

Out-of-office BP measurement refers to home BP monitoring and ambulatory BP monitoring. These two methods use different BP thresholds to define high BP than office-based methods do. The 2018 ESC/ESH statement’s best estimates for corresponding clinic BP, home BP monitoring, and ambulatory BP monitoring can be considered as a guide (Table 2).

Although most randomised controlled trials have used clinic BP as the reference, the HKCP acknowledges the growing body of evidence surrounding the use of home and ambulatory BP monitoring in the diagnosis and monitoring of hypertension and endorses the wider use of both methods.

Thresholds for initiation of antihypertensive medications

Both the European and American guidelines adopt a risk-based approach to treatment. Screening for and management of other cardiovascular disease risk factors common in hypertensive patients is recommended. The European guideline uses the Systematic COronary Risk Evaluation system to estimate the 10-year risk of a first fatal atherosclerotic event in relation to age, sex, smoking habits, total cholesterol level, and SBP. It is based on large, representative European cohort datasets with correction factors for different first-generation immigrants to Europe. Very high risk, high risk, and moderate risk correspond to calculated 10-year Systematic COronary Risk Evaluation risk values of ≥10%, ≤10% to <10%, and ≤1% to <5%, respectively. Hypertensive patients with documented cardiovascular disease, diabetes mellitus, chronic kidney disease (stage 3-5), and very high levels of individual risk factors (including grade 3 hypertension) are automatically considered to be at high or very high risk.

The American guideline recommends using the ACC/AHA Pooled Cohort Equations to estimate the 10-year risk of atherosclerotic cardiovascular disease and to guide treatment in mild hypertension. The results cannot be generalised to other age and ethnic groups, and there are no correction factors to refine the risk calculations for Asian populations.

According to the 2018 ESC/ESH guideline, patients with grade 2 and 3 hypertension should be treated with BP-lowering drug treatment and lifestyle interventions. In patients with grade 1 hypertension (BP 140-159/90-99 mm Hg) at high risk of cardiovascular disease or with hypertension-mediated organ damage, drug treatment should also be initiated simultaneously with lifestyle interventions. In low- to moderate-risk patients with grade 1 hypertension, BP-lowering drug treatment should be initiated after 3 to 6 months if BP is not controlled by lifestyle interventions alone. Drug treatment in adults with high normal BP (130-139/85-89 mm Hg) should only be considered in very high-risk situations with the presence of established cardiovascular disease, especially coronary artery disease (Fig²). In fit, older patients with hypertension (aged ≥80 years), BP-lowering
drug treatment and lifestyle interventions are recommended when SBP ≥160 mm Hg and/or DBP ≥90 mm Hg.

The HKCP supports the direction of a risk-based approach to treatment decision making and echoes the 2018 ESC/ESH approach. The HKCP recommends that patients seek physicians’ advice and that individualised treatment be provided after a comprehensive assessment of the patient’s clinical profile, risk factors, and preferences.

**Blood pressure treatment targets**

The American guideline recommends lowering BP to <130/80 mm Hg for adults, except in older patients (aged ≥65 years, noninstitutionalised, ambulatory, community-living adults), in whom the target is SBP <130 mm Hg. This one-size-fits-all BP goal raises much concern, especially for the elderly population. In contrast, the American College of Physicians and the American Academy of Family Physicians recommend pharmacological treatment to a target of SBP <150 mm Hg in adults aged ≥60 years who have persistently elevated SBP (≥150 mm Hg) and to a target of SBP <140 mm Hg in selected patients with high cardiovascular risk.

The European guideline establishes target ranges. The first objective is to lower BP to <140/90 mm Hg in all patients, and provided that treatment is well tolerated, treated BP values should be targeted to ≤130/80 mm Hg in most patients. In patients aged <65 years who are receiving BP-lowering drugs, it is recommended that SBP be lowered to 120 to 129 mm Hg in most patients. If the BP value reaches 120/70 mm Hg, a step-down of drug treatment should be considered, with close BP monitoring during follow-up. In older patients (aged ≥65 years) and in patients with chronic kidney disease, the SBP target should be less aggressive: 130 to 139 mm Hg. A DBP target range of 70 to 79 mm Hg is considered for all hypertensive patients, independent of risk level and co-morbidities.

The HKCP concurs with the 2018 ESC/ESH guideline in specifying target ranges for both SBP and DBP, with consideration of different age-groups and specific disease subgroups.

**Treatment strategies**

The European and American guidelines have much in common in terms of treatment strategies. Both recommend a similar array of non-pharmacological lifestyle interventions and drug treatments as the core strategy for BP reduction.

Non-pharmacological interventions are crucial in the prevention and management of high BP, either on their own or in combination with pharmacological therapy. These include weight reduction, heart-healthy diet, sodium reduction, physical exercise, smoking cessation, and moderation in alcohol intake.

The core drug treatment is based on four major classes: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and thiazide/thiazide-like diuretics. Beta
blocks are used when there is a specific indication (e.g., heart failure, angina, post myocardial infarction, or heart rate control). Both guidelines recommend the initiation of treatment in most patients with a single-pill combination containing two drugs to improve adherence and BP control. It is reasonable to use monotherapy in frail older patients and those at low risk with mild hypertension.

The HKCP assigns major importance to non-pharmacological interventions, both at the societal and individual patient levels. The HKCP sees the recent guideline publications as good opportunities to increase public awareness about hypertension and to encourage lifestyle modifications among the local population.

The HKCP agrees with the 2018 ESC/ESH guideline’s drug treatment algorithm and the initiation of a two-drug combination in most patients. Monotherapy is recommended in frail older patients and those at low risk with mild hypertension.

Specific considerations for geriatric patients

Older patients are characterised by clinical heterogeneity. A multi-dimensional assessment is required to assess the biological age of each individual patient, as well as the risks and benefits of tight BP control. For patients aged 65 to 79 years with few co-morbidities who are biologically young, the target SBP should be 130 to 139 mm Hg, provided that a medication burden is acceptable. For patients aged ≥80 years, or patients aged 65 to 79 years with multiple co-morbidities who are biologically old (i.e., frail), the optimal BP targets are not yet defined and have to be individualised. A treatment goal of SBP of 130 to <150 mm Hg can be considered, as suggested by other professional societies. Careful monitoring for any adverse effects or tolerability problems associated with BP-lowering treatment is required in frail and dependent older adults. Monotherapy rather than a single-pill combination is the preferable initial pharmacotherapy according to the 2018 ESC/ESH guideline.

Specific considerations for renal patients

Patients with chronic kidney disease should be considered as having high cardiovascular risk. Adequate hypertension control is important for reducing the rate of renal function deterioration as well as cardiovascular protection. The BP targets should be tailored according to age, tolerability, and the level of proteinuria. For diabetic and non-diabetic patients with albumin excretion rates of <30 mg per 24 hours (or equivalent), the suggested BP target is ≤130/80 mm Hg. The available evidence is inconclusive but does not prove that a BP target of <130/80 mm Hg improves clinical outcomes more than a target of <140/90 mm Hg in adults with chronic kidney disease.

Specific considerations for diabetic patients

Diabetes in combination with hypertension magnifies the risk of diabetes-related complications. Control of BP reduces the risk of microvascular (retinopathy and nephropathy) and macrovascular (especially stroke) complications. A BP goal of below 130/80 mm Hg is appropriate for individuals with diabetes, particularly those with established kidney, eye, or cerebrovascular damage, provided that the medication burden is acceptable.

Author contributions

All authors contributed to the concept of the manuscript, acquisition of data, analysis and interpretation of data, drafting of the article and critical revision for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Conflicts of interest

As an editor of the journal, BPY Yan was not involved in the peer review process. Other authors have disclosed no conflicts of interest.

Funding/support

This medical practice paper received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection,